Advertisement

Should Upfront Chemotherapy Precede Preoperative Chemoradiotherapy and Surgery in Locally Advanced Rectal Cancer?

  • Carlos Fernandez-Martos
  • Javier Gallego
  • Thomas J George
Chapter

Abstract

Treatment of micrometastasis should now be the focus of major interest in the treatment of locally advanced rectal cancer because distant metastases remain the leading cause of mortality in this population. In stage II and III rectal cancer, even in modern series, after preoperative treatment with short-course radiotherapy (SCRT) or chemoradiation (CRT) and total mesorectal excision (TME) with or without adjuvant chemotherapy (CT), 5-year distant relapse is about 35%, and local relapses are about 8% [1]. However, the role of adjuvant CT after CRT is still controversial.

References

  1. 1.
    Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cáncer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomised phase III trial. Ann Oncol 26:696–701CrossRefPubMedGoogle Scholar
  2. 2.
    Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190CrossRefPubMedGoogle Scholar
  3. 3.
    Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 25:1356–1362CrossRefPubMedGoogle Scholar
  4. 4.
    Sainato A, Cernusco Luna Lunzia V, Valentini V et al (2014) No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113:223–229CrossRefPubMedGoogle Scholar
  5. 5.
    MetaanalisisGoogle Scholar
  6. 6.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMedGoogle Scholar
  7. 7.
    Hong Y, Nam B, Kim K et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253CrossRefPubMedGoogle Scholar
  8. 8.
    Chua Y, Barbachano Y, Cunningham D et al (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defi ned poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11:241–248CrossRefPubMedGoogle Scholar
  9. 9.
    Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiation followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiation and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 28(5):859–865CrossRefPubMedGoogle Scholar
  10. 10.
  11. 11.
    Nogue M, Salud A, Vicente P et al (2011) Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging–defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 16:614–620CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schou JV, Larsen FO, Rasch L et al (2012) Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 23:2627–2633CrossRefPubMedGoogle Scholar
  13. 13.
    Cercek A, Goodman KA, Hajj C et al (2014) Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 12:513–519CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Perez K, Safran H, Sikov W et al. (2014) Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE Study. Am J Clin Oncol. [Epub ahead of print]Google Scholar
  15. 15.
    Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26(8):1722–1728Google Scholar
  16. 16.
    Marechal R, Vos B, Polus M et al (2012) Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 23:1525–1530CrossRefPubMedGoogle Scholar
  17. 17.
    Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30(14):1620–1627CrossRefPubMedGoogle Scholar
  18. 18.
    Sclafani F, Gonzalez D, Cunningham D et al (2014) TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst 106(7):pii: dju121CrossRefGoogle Scholar
  19. 19.
    O'Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol 32(18):1927–1934. [PMID: 24799484]CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29(20):2773–2780. [PMID: 21606427]CrossRefPubMedGoogle Scholar
  21. 21.
    Gérard J-P, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558–4565. [PMID: 23109696]CrossRefPubMedGoogle Scholar
  22. 22.
    Lin SH, George TJ, Ben-Josef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence T, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung C (2013) Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst 105(10):686–693. [PMID: 23503600]CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32(6):513–518. [PMID: 24419115]CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Fernandez-Martos C, Brown G, Estevan R et al (2014) Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 phase II multicenter trial. Oncologist 19:1042–1043CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gollins S, Sebag-Montefiore D, Adams R, Saunders MP, Grieve R, Scott N, Brown G, Quirke P, Butlin L, Ray R, Griffiths G, Hurt C (2015) A phase II single arm feasibility trial of neoadjuvant chemotherapy (NAC) with oxaliplatin/fluorouracil (OxMdG) then short-course preoperative radiotherapy (SCPRT) then immediate surgery in operable rectal cancer (ORC): COPERNICUS (NCT01263171). J Clin Oncol 33(suppl):abstr 3609Google Scholar
  26. 26.
    Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CA, Nagtegaal ID, Wiggers T, Glimelius B (2013) Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial (NCT01558921). BMC Cancer 13:279. [PMID: 23742033]CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A (2012) Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. (NCT00904813). Br J Surg 99(4):577–583. [PMID: 22241246]CrossRefPubMedGoogle Scholar
  28. 28.
    Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Bailão Aguilar P, Nadalin W, Perez RO (2013) Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 56(10):1109–1117. [PMID: 24022527]CrossRefPubMedGoogle Scholar
  29. 29.
    Roh M, Colangelo L, O’Connell M et al (2009) Preoperative multimodality therapy improves diseasefree survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cervantes A, Glynne-Jones R (2015) Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: one size does not fit all. Ann Oncol 26(4):617–619CrossRefPubMedGoogle Scholar
  31. 31.
    Perez K (2014) Have we put the cart before the horse? Reordering treatments for rectal cancer. Colorectal Cancer 3(4):311–313CrossRefGoogle Scholar
  32. 32.
    Lahaye MJ, Engelen SME, Nelemans PJ et al (2005) Imaging for predicting the risk factors – the circumferential resection margin and nodal disease – of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MRI 26:259–268CrossRefGoogle Scholar
  33. 33.
    Merkel S, Mansmann U, Siassi M et al (2001) The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Color Dis 16:298–304CrossRefGoogle Scholar
  34. 34.
    Nagtegaal I, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303–312CrossRefPubMedGoogle Scholar
  35. 35.
    Brown G, Radcliffe AG, Newcombe RG et al (2003) Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90:355–364CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Carlos Fernandez-Martos
    • 1
  • Javier Gallego
    • 2
  • Thomas J George
    • 3
  1. 1.Fundacion Instituto Valenciano de OncologiaValenciaSpain
  2. 2.Hospital General Universitario ElcheAlicanteSpain
  3. 3.University of Florida Health Cancer CenterGainesvilleUSA

Personalised recommendations